Transfusion reactions

Castillo, Brian; Dasgupta, Amitava; Klein, Kimberly; Tint, Hlaing; Wahed, Amer

doi:10.1016/b978-0-12-814313-1.00003-4

Cited by 12 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C (C or c) and E (E or e) are co-express due to their proximity. The genotype distribution of C (68%Caucasian, 27%Black, and 93%Asian), c (80%Caucasian, 96%Black, and 47%Asian), E (29%Caucasian, 22%Black, and 39%Asian), and e (98%Caucasian, 98%Black, and 96%Asian)[15] is in agreement with the previous reports suggest isoimmunization against E and c is more common in the Chinese population[1,3]. In our results, only 5 HDN were associated with anti-D antibody.…”

Section: Discussionsupporting

confidence: 92%

Rh-incompatible hemolytic disease of the newborn in Hefei

Jiang

Dai

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUNDAnti-D antibody is not the common cause of Rh-isoimmunization in Chinese neonatal jaundice. Recent change in national population policy has followed by an increase in Rh-isoimmunization related hemolytic disease of the newborn (HDN). Unfortunately, regional status of Rh-HDN is unavailable. We hypothesize that Rh-HDN in our region is most commonly due to anti-E antibody.AIMTo investigate the prevalence of hemolytic disease of the newborn due to Rh-isoimmunization in Hefei City.METHODSRetrospective review of data obtained from Children’s Hospital of Anhui and Hefei Blood Center between January 2017 and June 2019. Status of minor blood group antibody was studied in the corresponding mothers.RESULTSTotally 4138 newborns with HDN admitted during the study period and 116 (2.8%) received blood exchange transfusion (BET). Eighteen newborns (0.43%) with proven Rh-incompatible HDN were identified. All were not the first-born baby. Thirteen mothers were RhD (+) (72%) and five were RhD (-). The distribution of Rh-related antibodies in mothers was ten anti-E (55%), five anti-D (27%), and for one anti-C, anti-c, and anti-E/c (6%) each. Thirteen (72.2%) were qualified for BET, relative risk for BET was 28.9 as compared to other types of HDN, but only 10 received due to parenteral refusal. All (100%) RhD related HDN received BET which is not significantly different from RhE related HDN (81.8%).CONCLUSIONAs expected, all Rh-incompatible HDN newborns were not the first-born. Contrary to the Caucasian population, anti-D induced HDN is not the most common etiology. In our region, anti-E (11/18, 61%) is the most common cause of Rh-HDN.

show abstract

Section: Discussionsupporting

confidence: 92%

Rh-incompatible hemolytic disease of the newborn in Hefei

Jiang

Dai

et al. 2019

WJCC

View full text Add to dashboard Cite

show abstract

“…Each blood donation is tested for ABO and Rhesus blood groups and irregular antierythrocyte antibodies, using serological and in some cases sequence-specific primer (PCR-SSP) technology. ABO testing is mandatory to confirm blood product compatibility [27], as major incompatibility may induce severe or even lethal haemolytic transfusion reactions [28][29][30][31]. For serological typing, anti-A and anti-B sera are used to detect their target antigens on erythrocytes (forward type).…”

Section: Donor Blood Group Testing and Antibody Screeningmentioning

confidence: 99%

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Oeller

Laner-Plamberger

Krisch

et al. 2021

IJMS

View full text Add to dashboard Cite

Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.

show abstract

“…Some authors have reported that allergic reactions represent the most common TR, 4 , 11 in contrast to FNHTR reported by a few others. 12 – 14 The TR occurrence contributed by different types of blood products is also variable. 4 , 11 – 15 These variations are attributable to differences in the premedication used, patient characteristics, product manufacturing processes, storage times, use of LR and the reporting and monitoring systems used in different studies.…”

Section: Discussionmentioning

confidence: 99%

“… 12 – 14 The TR occurrence contributed by different types of blood products is also variable. 4 , 11 – 15 These variations are attributable to differences in the premedication used, patient characteristics, product manufacturing processes, storage times, use of LR and the reporting and monitoring systems used in different studies. In this current study, the occurrence of FNHTR associated with PRBC, platelet and plasma transfusions was 8.7%, 3.1%, and 0.3% (85 of 981 PRBC, 23 of 731 platelet and one of 332 plasma transfusions), respectively; and that of allergic reactions associated with PRBC, platelet and plasma transfusions was 1.9%, 6.3% and 5.1% (19 of 981 PRBC, 46 of 731 platelet and 17 of 332 plasma transfusions), respectively.…”

Section: Discussionmentioning

confidence: 99%

Investigation of the patients with recurrent acute transfusion reactions: A single tertiary medical centre experience

2023

View full text Add to dashboard Cite

Objective To assess the spectrum of patients who developed recurrent acute transfusion reactions (TRs) and to characterize these recurrent TRs. Methods This retrospective study included patients who developed ≥2 acute TRs between April 2017 and March 2020 in a tertiary medical centre. Results Among 216 TRs that occurred after 2024 transfusions in 87 patients, 66 (75.9%) patients reported a history of transfusions before the first TR and 70 (80.5%) patients received further transfusions after the last TR; with the same type of TR and reaction to the same type of blood product observed in 59 (67.8%) patients and 56 (64.4%) patients, respectively. TRs were most commonly associated with packed red blood cell (PRBC) transfusions and a febrile non-haemolytic transfusion reaction (FNHTR) was the most common type of TR. However, leukocyte reduced (LR) PRBCs were less common than LR platelets among transfusions with TR (22.7% [27/119] versus 75.0% [57/76], respectively) and premedication was prescribed before 196 of 216 (90.7%) transfusions with TR. Conclusion Most patients with recurrent TRs received repeated transfusions in addition to transfusions with TR. Instead of considering premedication, an increase in the use of LR might be the strategy to reduce the recurrence of TR.

show abstract

Transfusion reactions

Cited by 12 publications

References 10 publications

Rh-incompatible hemolytic disease of the newborn in Hefei

Rh-incompatible hemolytic disease of the newborn in Hefei

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Investigation of the patients with recurrent acute transfusion reactions: A single tertiary medical centre experience

Contact Info

Product

Resources

About